Faculty, Centre for Health Services and Policy Research
Associate Professor, UBC School of Population and Public Health
Director, Academy of Translational Medicine
Profile
Dr Dean Regier is an Associate Professor at the UBC School of Population and Public Health and the Centre for Health Services and Policy Research and the Director of the UBC Faculty of Medicine’s Academy of Translational Medicine.
An internationally recognized health economist specializing in regulatory science, Dr Regier collaborates with diverse stakeholders to develop policies and practices that accelerate access to safe, effective, and sustainable healthcare. His research has significantly advanced methodologies and evidence generation to promote equitable access to genetic and genomic technologies, particularly in precision oncology and rare diseases.
Dr Regier previously served as a Senior Scientist at BC Cancer, where he founded the Canadian Network for Learning Healthcare Systems and Cost-effective ‘Omics Innovation (CLEO). Through CLEO, he led provincial and national initiatives aimed at establishing learning healthcare systems that integrate data platforms, patient-oriented clinical trials, and AI-supported real-world evidence generation to inform precision oncology implemented. He also previously served as the economist appointed by BC’s Minister of Health to the Drug Benefit Council, he provided evidence-informed recommendations on the inclusion of therapeutics in BC’s PharmaCare formulary.
As Director of the UBC Faculty of Medicine Academy of Translational Medicine (ATM), Dr Regier will establish a globally recognized network and centre of excellence in translational medicine and regulatory science. Having previously created Canada’s sole educational initiative in Regulatory Science, Dr Regier will enhance and expand the ATM’s educational programs, further strengthening the life sciences and health policy research ecosystem across UBC and BC. Under his leadership, the ATM will serve as a central hub for collaboration and innovation, fostering greater integration among leading research institutes, centres, and programs to position BC as a powerhouse in translational medicine on the global stage.
Education
PhD, Health Economics, University of Aberdeen, UK
MA, Economics, Carleton University
BA (High Honors), Economics, University of Saskatchewan
Recent Publications
Cupples G, Krebs E, Weymann D, Ho C, Regier DA. Adopting life-cycle HTA: A tumour-agnostic precision oncology index economic evaluation from publicly-available reimbursement reviews. Int J Technol Assess Health Care. 2025 Jun 24:1-31. doi: 10.1017/S0266462325100111. Online ahead of print.
McTaggart-Cowan H, Zadravec K, Rafn BS, Raymakers AJN, Regier DA, Campbell KL. Using a Discrete Choice Experiment to Elicit Patient Preferences for Physical Therapist Services after Surgery for Breast Cancer. Phys Ther. 2025 May 29:pzaf077. doi: 10.1093/ptj/pzaf077. Online ahead of print.
Smith HS, Buchanan J, Goranitis I, IJzerman MJ, Lavelle TA, Marshall DA, Regier DA, Ungar WJ, Weymann D, Wordsworth S, Phillips KA, Jansen JP. Distributional Cost-Effectiveness Analysis in Genomic Medicine: Considerations for Addressing Health Equity. Value Health. 2025 May 6:S1098-3015(25)02327-7. doi: 10.1016/j.jval.2025.04.2162. Online ahead of print.
Krebs E, Bubela T, McPhail M, McCabe C, Regier DA. Putting the substance in substantial evidence: an evidence-based approach to flexible drug regulation. Front Med (Lausanne). 2025 Mar 20;12:1337890. doi: 10.3389/fmed.2025.1337890. eCollection 2025.
Krebs E, Weymann D, Ho C, Weppler A, Bosdet I, Karsan A, Hanna TP, Pollard S, Regier DA. Clinical Effectiveness and Cost-Effectiveness of Multigene Panel Sequencing in Advanced Melanoma: A Population-Level Real-World Target Trial Emulation. JCO Precis Oncol. 2025 Jan;9:e2400631. doi: 10.1200/PO-24-00631. Epub 2025 Feb 21.
Smith HS, Regier DA, Goranitis I, Bourke M, IJzerman MJ, Degeling K, Montgomery T, Phillips KA, Wordsworth S, Buchanan J, Marshall DA. Approaches to Incorporation of Preferences into Health Economic Models of Genomic Medicine: A Critical Interpretive Synthesis and Conceptual Framework. Appl Health Econ Health Policy. 2025 May;23(3):337-358. doi: 10.1007/s40258-025-00945-0. Epub 2025 Jan 20.
Hermansen A, Pollard S, McGrail K, Bansback N, Regier DA. Heuristics Identified in Health Data-Sharing Preferences of Patients With Cancer: Qualitative Focus Group Study. J Med Internet Res. 2024 Dec 17;26:e63155. doi: 10.2196/63155.
Krebs E, Weymann D, Ho C, Bosdet I, Laskin J, Lim HJ, Yip S, Karsan A, Hanna TP, Pollard S, Regier DA. Real-world cost-effectiveness of multi-gene panel sequencing to inform therapeutic decisions for advanced non-small cell lung cancer: a population-based study. Lancet Reg Health Am. 2024 Nov 15;40:100936. doi: 10.1016/j.lana.2024.100936. eCollection 2024 Dec.
Pataky RE, Peacock S, Bryan S, Sadatsafavi M, Regier DA. Using Genomic Heterogeneity to Inform Therapeutic Decisions for Metastatic Colorectal Cancer: An Application of the Value of Heterogeneity Framework. Appl Health Econ Health Policy. 2025 May;23(3):441-452. doi: 10.1007/s40258-024-00926-9. Epub 2024 Nov 9.
Ehman M, Caron NR, Montour L, Regier DA. Qualitative genomic research with Indigenous peoples: a scoping review of participatory practice. BMJ Glob Health. 2024 Oct 17;9(10):e015377. doi: 10.1136/bmjgh-2024-015377.